Cusatuzumab
As of the edition of 20 October 2026, Cusatuzumab is an antibody: in active development; acts on CD70.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2027
- Kind
- Antibody
- Registered trials
- 8, 1 stopped early
- Disease areas
- Cancer; Blood and lymph
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| CD70 | CD70 antigen | P32970 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 3 | 2 | 1 | 0 |
| Phase 2 | 5 | 2 | 2 | 1 |
| All trials | 8 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| OncoVerity | Lead sponsor of trials | 2013 to now |
| argenx | Lead sponsor of trials | 2015 to now |
| Johnson & Johnson | Lead sponsor of trials | 2021 to now |